title: [Preparation, analysis and anti-anemic action of peroral powders with ferrous oxalate. Ferosol-1].
abstract: Investigation of new stable iron (II) compounds is still an actual problem of today. Therefore we synthesized ferrous oxalate and prepared a stable antianaemic powder Ferosol-1 including copper, zinc and cobalt. We used colour tests, precipitation reactions and paper chromatography for identification of components of this powder. Quantitative analysis of iron and other elements was performed using atomic absorption spectroscopy. We used Lichfield and Wilkinson method modificated by Roth to detect acute Ferosol-1 toxicity. To estimate a local action of this powder we used guinea pigs which were grouped into control and trial ones. We determined bioavailability of Ferosol-1 by giving it to rabbits with experimental posthemorrhagic anemia. Iron resorption was tested on 20-25 days old piglets. We also tried this drug on newborn piglets while atching their weight gain and calculation daily weight gain. This data was used to estimate indirect impact of Ferosol-1 on metabolism of piglets. According to our data Ferosol-1 is of low toxicity (LD50 = 2.25 g/kg), it does not irritate mucosa of duodenum and ventriculus and could be used orally. Iron from Ferosol-1 was found to be well assimilated and to take place in hemopoetic processes of rabbit. After administration of Ferosol-1 to piglets iron concentration in their serum increased from 35.03 +/- 0.66 to 54.88 +/- 6.63 mumol/l, hemoglobin concentration increased to 96.4 +/- 2.5 g/l, erythrocyte number increased to 4.4 +/- 0.14 x 10(12)/l. The same data of control piglets were respectively 83.7 +/- 3.1 g/l and 3.52 +/- 0.3 x 10(12)/l. According to our results Ferosol-1 is an effective drug for prevention of iron-deficiency anemia and causes slight weight gain of piglets.
authors.affiliation: Kauno medicinos universitetas, Mickeviciaus 9, 3000 Kaunas. npalma@takas.lt
authors.forename: Palma
authors.initials: P
authors.lastname: Nenortiene
authors.forename: Marija
authors.initials: M
authors.lastname: Sapragoniene
authors.forename: Antanas
authors.initials: A
authors.lastname: Stankevicius
authors.forename: Algimantas Petras
authors.initials: AP
authors.lastname: Matusevicius
authors.forename: Gintaras
authors.initials: G
authors.lastname: Daunoras
mesh_terms: D000284:Administration, Oral; D018798:Anemia, Iron-Deficiency / Q000097:blood / Q000188:drug therapy* / Q000378:metabolism / Q000517:prevention & control; D000818:Animals; D000831:Animals, Newborn; D011232:Chemical Precipitation; D002854:Chromatography, Paper; D003035:Cobalt / Q000032:analysis; D003300:Copper / Q000032:analysis; D005260:Female; D005296:Ferrous Compounds / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use* / Q000633:toxicity; D006168:Guinea Pigs; D006410:Hematopoiesis; D006454:Hemoglobins / Q000032:analysis; D007501:Iron / Q000378:metabolism; D008297:Male; D010070:Oxalates / Q000008:administration & dosage / Q000627:therapeutic use; D011208:Powders; D011817:Rabbits; D013552:Swine; D015032:Zinc / Q000032:analysis
chemical_list: D005296:Ferrous Compounds; D006454:Hemoglobins; D010070:Oxalates; D011208:Powders; D003035:Cobalt; D003300:Copper; D007501:Iron; D015032:Zinc